These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24290338)

  • 1. Attitudes toward supplementary criteria in the reimbursement process in Poland.
    Kolasa K; Annemans L; Lees M
    Int J Technol Assess Health Care; 2013 Oct; 29(4):443-9. PubMed ID: 24290338
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
    Malinowski KP; Kawalec P; Trąbka W
    Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector?
    Kolasa K
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):751-62. PubMed ID: 25052370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness decision making and US public opinion.
    Botta MD; Blendon RJ; Benson JM
    JAMA Intern Med; 2014 Jan; 174(1):141-3. PubMed ID: 24100698
    [No Abstract]   [Full Text] [Related]  

  • 5. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
    Kawalec P; Malinowski KP
    Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better defining target populations for drugs with a view to reimbursement.
    Massol J; Boissel JP
    Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
    Postma MJ; Boersma C; Vandijck D; Vegter S; Le HH; Annemans L
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):367-9. PubMed ID: 21831013
    [No Abstract]   [Full Text] [Related]  

  • 12. The paradox of public participation in the healthcare in Poland--what citizens want, and what they think.
    Kolasa K; Dohnalik J; Borek E; Siemiątkowski M; Scibiorski C
    Health Policy; 2014 Nov; 118(2):159-65. PubMed ID: 25445113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of radiology in Japan: report of a pilot study at three hospitals.
    Katayama H
    Acad Radiol; 1996 Apr; 3 Suppl 1():S101-5. PubMed ID: 8796529
    [No Abstract]   [Full Text] [Related]  

  • 14. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.
    Kolasa K; Schubert S; Manca A; Hermanowski T
    Health Policy; 2011 Oct; 102(2-3):145-51. PubMed ID: 21641074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten arguments for a societal perspective in the economic evaluation of medical innovations.
    Jönsson B
    Eur J Health Econ; 2009 Oct; 10(4):357-9. PubMed ID: 19618224
    [No Abstract]   [Full Text] [Related]  

  • 18. The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland.
    Bochenek T; Kocot E; Rodzinka M; Godman B; Maciejewska K; Kamal S; Pilc A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):385-400. PubMed ID: 27882823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Knowledge of and opinions on epilepsy among inhabitants of large towns].
    Zieliński JJ
    Neurol Neurochir Pol; 1973; 7(5):639-44. PubMed ID: 4763003
    [No Abstract]   [Full Text] [Related]  

  • 20. Painful dilemmas: A study of the way the public's assessment of animal research balances costs to animals against human benefits.
    Lund TB; Mørkbak MR; Lassen J; Sandøe P
    Public Underst Sci; 2014 May; 23(4):428-44. PubMed ID: 23825251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.